SCHEMBL2814634

SCHEMBL2814634

CC(C)Oc1cccc(OC(C)C)c1C=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.61
MAPT P10636 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
ALDH1A3 P47895 1/20 0.45
IRAK4 Q9NWZ3 2/20 0.44
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
ALDH1A1 P00352 4/20 0.42
ACHE P22303 1/20 0.42
MCHR1 Q99705 1/20 0.41
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TLR2 O60603 1/20 0.37
ERN1 O75460 1/20 0.37
TLR1 Q15399 1/20 0.37
TLR6 Q9Y2C9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4541926 0.92 CYP1A2 (0.54) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL17662362 0.88 MAPT (0.54) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL30092827 0.88 MAPT (0.54) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL4540583 0.87 CYP1A2 (0.53) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL1427814 0.84 MAPT (0.50) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL677274 0.80 MCHR1 (0.46) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL21850064 0.79 CYP1A2 (0.46) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL11212238 0.78 CYP1A2 (0.44) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL24026496 0.77 CYP1A2 (0.41) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3
SCHEMBL19583184 0.77 CYP1A2 (0.41) CYP1A2MAPTCYP2C9CYP2C19ALDH1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120209007-A9 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2012-08-16 US disclosed
US-20110319629-A1 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-12-29 US disclosed
EP-2396289-A1 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES Agency For Science, Technology And Research (SG) 2011-12-21 EP disclosed
US-20100249443-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-09-30 US disclosed
WO-2010093336-A1 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-08-19 WO disclosed
WO-2010093327-A1 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-08-19 WO disclosed
US-20100185000-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-07-22 US disclosed
US-20100179343-A1 METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-07-15 US disclosed
US-7732544-B2 Titanium compound and process for producing optically active cyanohydrins MITSUI CHEMICALS, INC. (JP) 2010-06-08 US disclosed
EP-2190851-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES Agency for Science, Technology and Research (SG) 2010-06-02 EP disclosed
WO-2009041919-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-04-02 WO disclosed
WO-2008121074-A1 METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2008-10-09 WO disclosed
WO-2008121076-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2008-10-09 WO disclosed
US-20070265463-A1 Titanium Compound and Process for Producing Optically Active Cyanohydrins MITSUI CHEMICALS, INC. (JP) 2007-11-15 US disclosed
EP-1806336-A1 TITANIUM COMPOUND AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRINS Mitsui Chemicals, Inc. (JP) 2007-07-11 EP disclosed
US-6977315-B2 by nitroaldol reactions of aldehydes using an asymmetric catalyst; beta -nitroalcohols are important intermediates of optically active aminoalcohols which are useful as starting materials in synthesizing fine chemicals and drugs MITSUI CHEMICALS, INC. (JP) 2005-12-20 US disclosed
US-20050215832-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE NITROALCOHOLS MITSUI CHEMICALS, INC. (JP) 2005-09-29 US disclosed
EP-0210140-B1 INHIBITORS OF BENZYLAMINOXIDASES, SELECTIVE WITH RESPECT TO OTHER AMINOXIDASES CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1990-06-13 EP disclosed
US-4888283-A Selective inhibitors of benzylaminoxidases with respect to other aminoxidases CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1989-12-19 US disclosed
EP-0210140-A2 Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1987-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179343-A1 METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE TDO2, AOX1, DAO CYP1A2 1806/4885MAPT 4873/4885CYP2C9 2086/4885
US-20100185000-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES ABL1, CD59, TDO2 CYP1A2 474/4885MAPT 3880/4885CYP2C9 977/4885
US-20070265463-A1 Titanium Compound and Process for Producing Optically Active Cyanohydrins WNT1, C3AR1, TDO2 CYP1A2 776/4885MAPT 4693/4885CYP2C9 1161/4885
US-20050215832-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE NITROALCOHOLS CBR1, CBR3, NQO1 CYP1A2 152/4885MAPT 4481/4885CYP2C9 905/4885
US-20110319629-A1 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES ABL1, TYR, CD59 CYP1A2 487/4885MAPT 3932/4885CYP2C9 635/4885
US-20100249443-A1 TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES ABL1, CD59, TDO2 CYP1A2 474/4885MAPT 3880/4885CYP2C9 977/4885
US-20120209007-A9 TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES ABL1, TYR, CD59 CYP1A2 487/4885MAPT 3932/4885CYP2C9 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.